6:06 PM
 | 
Sep 04, 2007
 |  BC Extra  |  Clinical News

Clinical Data's vilazodone meets depression endpoint

CLDA said vilazodone met the primary endpoint in a Phase III trial (GNSC-04-DP-02) to treat depression by producing a significant...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >